Table 2. Summary of the results after hemolymph, bacterial, baculovirus-mediated dsJHER administration.

Type of administration	Targeted region	Time of administration	Total insects*	Control	Total insects* (Controltreatments)	Specific SnJHER silencing	Phenotype
Injection	472 bp	5thd3	100	dsL4440MCS	100	Yes	Absent
	1276 bp	5thd3	100	dsL4440MCS	100	Yes	Absent
	1725 bp	5thd3	100	dsL4440MCS	100	Yes	5% of melanized/fused epidermis
	472 bp	6thd9	100	dsL4440MCS	100	Yes	>90% of larval-pupal intermediates type I.
	1276 bp	6thd9	100	dsL4440MCS	100	Yes	>90% of larval-pupal intermediates type II.
	1725 bp	6thd9	100	dsL4440MCS	100	Yes	>90% of larval-pupal intermediates type III.
Bacterial feeding	472 bp	1std05thd0	100	HT115-L4440	100	Yes	Absent
	472 bp	1std06thd9	100	HT115-L4440	100	Yes	Absent
	472 bp	5thd05thd7	100	HT115-L4440	100	Yes	Absent
Baculovirus infection	472 bp	5thd3	200	dsLuciferase Virus	200	Yes	14% of melanized/fused epidermis
	472 bp	6thd9	200	dsLuciferase Virus	200	Yes	21% of larval-pupal intermediates type 3
	472 bp	Survived pupae from 6thd9 infections	78	dsLuciferase Virus	62	Yes	9% of scale-less adults

The asterisk indicates the total amount of insects used, among three independent trials, both for control and experimental groups.